David Cornblath

Research output

Research output per year 1973 1988 1989 1990 1991 1996 1998 2010 2019 2021 2023

• 219 Article
• 34 Review article
• 25 Letter
• 16 Editorial
• 12 More
  • 5 Comment/debate
  • 4 Chapter
  • 2 Short survey
  • 1 Conference contribution

Research output per year

Research output per year

Search results

• 2023

  CSF Findings in Relation to Clinical Characteristics, Subtype, and Disease Course in Patients With Guillain-Barré Syndrome

  Al-Hakem, H., Doets, A. Y., Stino, A. M., Zivkovic, S. A., Andersen, H., Willison, H. J., Cornblath, D. R., Gorson, K. C., Islam, Z., Mohammad, Q. D., Sindrup, S. H., Kusunoki, S., Davidson, A., Casasnovas, C., Bateman, K., Miller, J. A. L., Van Den Berg, B., Verboon, C., Roodbol, J., Leonhard, S. E., & 58 othersArends, S., Luijten, L. W. G., Benedetti, L., Kuwabara, S., Van Den Bergh, P., Monges, S., Marfia, G. A., Shahrizaila, N., Galassi, G., Pereon, Y., Burmann, J., Kuitwaard, K., Kleyweg, R. P., Marchesoni, C., Tous, M. J. S., Querol, L., Martin-Aguilar, L., Wang, Y., Nobile-Orazio, E., Rinaldi, S., Schenone, A., Pardo, J., Vermeij, F. H., Waheed, W., Lehmann, H. C., Granit, V., Stein, B., Cavaletti, G., Gutierrez-Gutierrez, G., Barroso, F. A., Visser, L. H., Katzberg, H. D., Dardiotis, E., Attarian, S., Van Der Kooi, A. J., Eftimov, F., Wirtz, P. W., Samijn, J. P. A., Jacobus Gilhuis, H., Hadden, R. D. M., Holt, J. K. L., Sheikh, K. A., Kolb, N., Karafiath, S., Vytopil, M., Antonini, G., Feasby, T. E., Faber, C., Kramers, H., Busby, M., Roberts, R. C., Silvestri, N. J., Fazio, R., Van Dijk, G. W., Garssen, M. P. J., Verschuuren, J., Harbo, T. & Jacobs, B. C., Jun 6 2023, In: Neurology. 100, 23, p. E2386-E2397

  Research output: Contribution to journal › Article › peer-review

  • Cell Count 100%
  • Proteins 81%
  • Miller Fisher Syndrome 68%
  • Odds Ratio 57%
  • Neural Conduction 49%

• European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain–Barré syndrome

  van Doorn, P. A., Van den Bergh, P. Y. K., Hadden, R. D. M., Avau, B., Vankrunkelsven, P., Attarian, S., Blomkwist-Markens, P. H., Cornblath, D. R., Goedee, H. S., Harbo, T., Jacobs, B. C., Kusunoki, S., Lehmann, H. C., Lewis, R. A., Lunn, M. P., Nobile-Orazio, E., Querol, L., Rajabally, Y. A., Umapathi, T., Topaloglu, H. A., & 1 othersWillison, H. J., Dec 2023, In: European Journal of Neurology. 30, 12, p. 3646-3674 29 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Neurology 100%
  • Peripheral Nerves 92%
  • Guidelines 60%
  • Advisory Committees 44%
  • Intravenous Immunoglobulins 35%

• European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain–Barré syndrome

  van Doorn, P. A., Van den Bergh, P. Y. K., Hadden, R. D. M., Avau, B., Vankrunkelsven, P., Attarian, S., Blomkwist-Markens, P. H., Cornblath, D. R., Goedee, H. S., Harbo, T., Jacobs, B. C., Kusunoki, S., Lehmann, H. C., Lewis, R. A., Lunn, M. P., Nobile-Orazio, E., Querol, L., Rajabally, Y. A., Umapathi, T., Topaloglu, H. A., & 1 othersWillison, H. J., Dec 2023, In: Journal of the Peripheral Nervous System. 28, 4, p. 535-563 29 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Neurology 100%
  • Peripheral Nerves 92%
  • Guidelines 60%
  • Advisory Committees 44%
  • Intravenous Immunoglobulins 35%

• IgM anti-MAG^± peripheral neuropathy (IMAGiNe) study protocol: An international, observational, prospective registry of patients with IgM M-protein peripheral neuropathies

  the IMAGiNe Consortium, Jun 2023, In: Journal of the Peripheral Nervous System. 28, 2, p. 269-275 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Myelin-Associated Glycoprotein 100%
  • anti-IgM 83%
  • Peripheral Nervous System Diseases 70%
  • Immunoglobulin M 59%
  • Registries 52%

• Peripheral Nerve Safety of Nerve Growth Factor Inhibition by Tanezumab: Pooled Analyses of Phase III Clinical Studies in Over 5000 Patients with Osteoarthritis

  Brown, M. T., Cornblath, D. R., Koltzenburg, M., Gorson, K. C., Hickman, A., Pixton, G. C., Gaitonde, P., Viktrup, L. & West, C. R., Jul 2023, In: Clinical Drug Investigation. 43, 7, p. 551-563 13 p.

  Research output: Contribution to journal › Article › peer-review

  • tanezumab 100%
  • Nerve Growth Factor 55%
  • Peripheral Nerves 50%
  • Osteoarthritis 45%
  • Psychological Inhibition 42%

• Safety and Tolerability of Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: Results of the ProCID Study

  Cornblath, D. R., van Doorn, P. A., Hartung, H. P., Merkies, I. S. J., Katzberg, H. D., Hinterberger, D. & Clodi, E., Sep 2023, In: Drug Safety. 46, 9, p. 835-845 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy 100%
  • Intravenous Immunoglobulins 79%
  • Safety 60%
  • Dose 54%
  • Thrombotic 18%
• 2022

  Analysis of relapse by inflammatory Rasch-built overall disability scale status in the PATH study of subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy

  the PATH study group, Jun 2022, In: Journal of the Peripheral Nervous System. 27, 2, p. 159-165 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Hizentra 100%
  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy 83%
  • Immunoglobulins 52%
  • Recurrence 34%
  • Intravenous Immunoglobulins 22%

• An International Perspective on Preceding Infections in Guillain-Barré Syndrome: The IGOS-1000 Cohort

  Leonhard, S. E., Van Der Eijk, A. A., Andersen, H., Antonini, G., Arends, S., Attarian, S., Barroso, F. A., Bateman, K. J., Batstra, M. R., Benedetti, L., Van Den Berg, B., Van Den Bergh, P., Bürmann, J., Busby, M., Casasnovas, C., Cornblath, D. R., Davidson, A., Doets, A. Y., Van Doorn, P. A., Dornonville De La Cour, C., & 53 othersFeasby, T. E., Fehmi, J., Garcia-Sobrino, T., Goldstein, J. M., Gorson, K. C., Granit, V., Hadden, R. D. M., Harbo, T., Hartung, H. P., Hasan, I., Holbech, J. V., Holt, J. K. L., Jahan, I., Islam, Z., Karafiath, S., Katzberg, H. D., Kleyweg, R. P., Kolb, N., Kuitwaard, K., Kuwahara, M., Kusunoki, S., Luijten, L. W. G., Kuwabara, S., Lee Pan, E., Lehmann, H. C., Maas, M., Martín-Aguilar, L., Miller, J. A. L., Mohammad, Q. D., Monges, S., Nedkova-Hristova, V., Nobile-Orazio, E., Pardo, J., Pereon, Y., Querol, L., Reisin, R., Van Rijs, W., Rinaldi, S., Roberts, R. C., Roodbol, J., Shahrizaila, N., Sindrup, S. H., Stein, B., Cheng-Yin, T., Tankisi, H., Tio-Gillen, A. P., Sedano Tous, M. J., Verboon, C., Vermeij, F. H., Visser, L. H., Huizinga, R., Willison, H. J. & Jacobs, B. C., Sep 20 2022, In: Neurology. 99, 12, p. E1299-E1313

  Research output: Contribution to journal › Article › peer-review

  • Internationality 100%
  • Campylobacter jejuni 44%
  • Infections 36%
  • Cytomegalovirus 27%
  • Hepatitis E virus 18%

• Electrodiagnosis of Guillain-Barre syndrome in the International GBS Outcome Study: Differences in methods and reference values

  the IGOS Consortium, Jun 1 2022, In: Clinical Neurophysiology. 138, p. 231-240 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Electrodiagnosis 100%
  • Guillain-Barre Syndrome 76%
  • Reference Values 49%
  • Health Care Outcome Assessment 40%
  • Publications 10%

• Electrodiagnostic subtyping in Guillain-Barré syndrome: Use of criteria in practice based on a survey study in IGOS

  the IGOS Electrophysiology Expertise Group, Sep 2022, In: Journal of the Peripheral Nervous System.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Action Potentials 100%
  • Muscles 66%
  • Electrophysiology 30%
  • Elbow 27%
  • Wrist 26%

• International Validation of the Erasmus Guillain–Barré Syndrome Respiratory Insufficiency Score

  the IGOS Consortium, Apr 2022, In: Annals of neurology. 91, 4, p. 521-531 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • North America 100%
  • Respiratory Insufficiency 87%
  • Artificial Respiration 71%
  • Northern Asia 30%
  • Calibration 19%

• Letter to the Editor re "Complete Foot Drop With Normal Electrodiagnostic Studies: Sunderland 'Zero' Ischemic Conduction Block of the Common Peroneal Nerve" by Peters and Colleagues

  Cornblath, D. R., Kiernan, M. C., Kimura, J., Koltzenburg, M., Lewis, R. A., Parry, G. J., Pollard, J. D. & Sumner, A. J., Oct 1 2022, In: Annals of plastic surgery. 89, 4, p. 343 1 p.

  Research output: Contribution to journal › Editorial › peer-review

• Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy

  Cornblath, D. R., Van Doorn, P. A., Hartung, H. P., Merkies, I. S. J., Katzberg, H. D., Hinterberger, D. & Clodi, E., Mar 1 2022, In: Brain. 145, 3, p. 887-896 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy 100%
  • Intravenous Immunoglobulins 59%
  • Panzyga 20%
  • Confidence Intervals 15%
  • Safety 15%

• Skin biopsy and small fibre neuropathies: Facts and thoughts 30 years later

  Lauria, G., Faber, C. G. & Cornblath, D. R., Sep 1 2022, In: Journal of Neurology, Neurosurgery and Psychiatry. 93, 9, p. 915-918 4 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
• 2021

  A recurrent MORC2 mutation causes Charcot-Marie-Tooth disease type 2Z

  Vujovic, D., Cornblath, D. R. & Scherer, S. S., Jun 2021, In: Journal of the Peripheral Nervous System. 26, 2, p. 184-186 3 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Charcot-Marie-Tooth Disease 100%
  • Vinblastine 89%
  • Electrophysiology 41%
  • Mutation 41%
  • Hodgkin Disease 37%

• COVID-19 vaccine and Guillain-Barré syndrome: Let's not leap to associations

  Lunn, M. P., Cornblath, D. R., Jacobs, B. C., Querol, L., Van Doorn, P. A., Hughes, R. A. & Willison, H. J., Feb 1 2021, In: Brain. 144, 2, p. 368-371 4 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access
  2 Scopus citations

• European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second revision

  Van den Bergh, P. Y. K., van Doorn, P. A., Hadden, R. D. M., Avau, B., Vankrunkelsven, P., Allen, J. A., Attarian, S., Blomkwist-Markens, P. H., Cornblath, D. R., Eftimov, F., Goedee, H. S., Harbo, T., Kuwabara, S., Lewis, R. A., Lunn, M. P., Nobile-Orazio, E., Querol, L., Rajabally, Y. A., Sommer, C. & Topaloglu, H. A., Nov 2021, In: European Journal of Neurology. 28, 11, p. 3556-3583 28 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy 100%
  • Neurology 75%
  • Peripheral Nerves 69%
  • Joints 50%
  • Guidelines 45%

• European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second revision

  Van den Bergh, P. Y. K., van Doorn, P. A., Hadden, R. D. M., Avau, B., Vankrunkelsven, P., Allen, J. A., Attarian, S., Blomkwist-Markens, P. H., Cornblath, D. R., Eftimov, F., Goedee, H. S., Harbo, T., Kuwabara, S., Lewis, R. A., Lunn, M. P., Nobile-Orazio, E., Querol, L., Rajabally, Y. A., Sommer, C. & Topaloglu, H. A., Sep 2021, In: Journal of the Peripheral Nervous System. 26, 3, p. 242-268 27 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy 100%
  • Neurology 75%
  • Peripheral Nerves 69%
  • Joints 50%
  • Guidelines 45%

• Guía basada en la evidencia. Diagnóstico y manejo del síndrome de guillain-barré en diez pasos

  Translated title of the contribution: Evidence based guidelines. Diagnosis and management of guillain-barré syndrome in ten steps.Leonhard, S. E., Mandarakas, M. R., Gondim, F. D. A. A., Bateman, K., Ferreira, M. L. B., Cornblath, D. R., Van doorn, P. A., Dourado, M. E., Hughes, R. A. C., Islam, B., Kusunoki, S., Pardo, C. A., Reisin, R., Sejvar, J. J., Shahrizaila, N., Soares, C., Umapathi, T., Wang, Y., Yiu, E. M., Willison, H. J., & 1 othersJacobs, B. C., Sep 1 2021, In: Medicina. 81, 5, p. 817-836 20 p.

  Research output: Contribution to journal › Article › peer-review

  • Guidelines 100%
  • Disease Outbreaks 45%
  • Polynesia 40%
  • Zika Virus 34%
  • Latin America 30%

• Guillain-Barré Syndrome Outbreak in Peru 2019 Associated with Campylobacter jejuni Infection

  Ramos, A. P., Leonhard, S. E., Halstead, S. K., Cuba, M. A., Castañeda, C. C., Dioses, J. A., Tipismana, M. A., Abanto, J. T., Llanos, A., Gourlay, D., Grogl, M., Ramos, M., Rojas, J. D., Meza, R., Puiu, D., Sherman, R. M., Salzberg, S. L., Simner, P. J., Willison, H. J., Jacobs, B. C., & 3 othersCornblath, D. R., Umeres, H. F. & Pardo, C. A., Mar 5 2021, In: Neurology: Neuroimmunology and NeuroInflammation. 8, 2, e952.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Campylobacter Infections 100%
  • Campylobacter jejuni 91%
  • Peru 89%
  • Disease Outbreaks 62%
  • Arbovirus Infections 23%
  1 Scopus citations

• Intravenous immunoglobulin treatment for mild Guillain-Barré syndrome: An international observational study

  Verboon, C., Harbo, T., Cornblath, D. R., Hughes, R. A. C., Van Doorn, P. A., Lunn, M. P., Gorson, K. C., Barroso, F., Kuwabara, S., Galassi, G., Lehmann, H. C., Kusunoki, S., Reisin, R. C., Binda, D., Cavaletti, G. & Jacobs, B. C., Oct 1 2021, In: Journal of Neurology, Neurosurgery and Psychiatry. 92, 10, p. 1080-1088 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Intravenous Immunoglobulins 100%
  • Observational Studies 69%
  • Therapeutics 14%
  • Selection Bias 11%
  • Muscle Strength 10%

• Maybe myopathic EMG but not myopathy

  Cornblath, D. R., Sep 2021, In: Clinical Neurophysiology. 132, 9, p. 2323 1 p.

  Research output: Contribution to journal › Letter › peer-review

• Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy

  the PATH study group, Aug 2021, In: CPT: Pharmacometrics and Systems Pharmacology. 10, 8, p. 839-850 12 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Immunoglobulin 100%
  • Pharmacokinetics 88%
  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy 87%
  • Linking 66%
  • Efficacy 65%

• Prospective evaluation of health care provider and patient assessments in chemotherapy-induced peripheral neurotoxicity

  on behalf of the CI-PeriNomS group, Aug 17 2021, In: Neurology. 97, 7, p. E660-E672

  Research output: Contribution to journal › Article › peer-review

  • Health Personnel 100%
  • Minimal Clinically Important Difference 97%
  • Drug Therapy 67%
  • Neoplasms 37%
  • Physicians 31%

• Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial

  Dutch GBS Study Group, Apr 2021, In: The Lancet Neurology. 20, 4, p. 275-283 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Intravenous Immunoglobulins 100%
  • Placebos 61%
  • Randomized Controlled Trials 60%
  • Intention to Treat Analysis 14%
  • Random Allocation 12%
  1 Scopus citations
• 2020

  A novel HSPB1 mutation associated with a late onset CMT2 phenotype: Case presentation and systematic review of the literature

  Taga, A. & Cornblath, D. R., Sep 1 2020, In: Journal of the Peripheral Nervous System. 25, 3, p. 223-229 7 p.

  Research output: Contribution to journal › Review article › peer-review

  • Systematic Reviews 100%
  • Phenotype 81%
  • Type 2F Charcot-Marie-Tooth disease 80%
  • Mutation 75%
  • Type II Distal Hereditary Motor Neuropathy 72%
  3 Scopus citations

• Boundaries of chronic inflammatory demyelinating polyradiculoneuropathy

  Van den Bergh, P. Y. K., van Doorn, P. A., Jacobs, B. C., Querol, L., Bunschoten, C. & Cornblath, D. R., Mar 1 2020, In: Journal of the Peripheral Nervous System. 25, 1, p. 4-8 5 p.

  Research output: Contribution to journal › Editorial › peer-review
  4 Scopus citations

• Fatigue in chronic inflammatory demyelinating polyradiculoneuropathy

  Peric, S. Z. & Cornblath, D. R., Dec 2020, In: Muscle and Nerve. 62, 6, p. 649-651 3 p.

  Research output: Contribution to journal › Editorial › peer-review
  1 Scopus citations

• Guillain-Barré syndrome in times of pandemics

  Leonhard, S. E., Cornblath, D. R., Endtz, H. P., Sejvar, J. J. & Jacobs, B. C., Oct 1 2020, In: Journal of Neurology, Neurosurgery and Psychiatry. 91, 10, p. 1027-1029 3 p.

  Research output: Contribution to journal › Editorial › peer-review

  Open Access
  3 Scopus citations

• Original research: Second IVIg course in Guillain-Barré syndrome with poor prognosis: The non-randomised ISID study

  Verboon, C., Van Den Berg, B., Cornblath, D. R., Venema, E., Gorson, K. C., Lunn, M. P., Lingsma, H., Van Den Bergh, P., Harbo, T., Bateman, K., Pereon, Y., Sindrup, S. H., Kusunoki, S., Miller, J., Islam, Z., Hartung, H. P., Chavada, G., Jacobs, B. C., Hughes, R. A. C. & Van Doorn, P. A., Feb 1 2020, In: Journal of Neurology, Neurosurgery and Psychiatry. 91, 2, p. 113-121 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Intravenous Immunoglobulins 100%
  • Motivation 5%
  • Observational Studies 5%
  • Health Care Outcome Assessment 4%
  10 Scopus citations

• Placebo effect in chronic inflammatory demyelinating polyneuropathy: The PATH study and a systematic review

  Lewis, R. A., Cornblath, D. R., Hartung, H. P., Sobue, G., Lawo, J. P., Mielke, O., Durn, B. L., Bril, V., Merkies, I. S. J., Bassett, P., Cleasby, A., van Schaik, I. N., Sabet, A., George, K., Roberts, L., Carne, R., Blum, S., Henderson, R., Van Damme, P., Demeestere, J., & 128 othersLarue, S., D’Amour, C., Kunc, P., Valis, M., Sussova, J., Kalous, T., Talab, R., Bednar, M., Toomsoo, T., Rubanovits, I., Gross-Paju, K., Sorro, U., Saarela, M., Auranen, M., Pouget, J., Attarian, S., Le Masson, G., Wielanek, A., Desnuelle, C., Delmon, E., Clavelou, P., Aufauvre, D., Schmidt, J., Zschuentzsch, J., Sommer, C., Kramer, D., Hoffmann, O., Goerlitz, C., Haas, J., Chatzopoulos, M., Yoon, R., Gold, R., Berlit, P., Jaspert-Grehl, A., Liebetanz, D., Kutschenko, A., Stangel, M., Trebst, C., Baum, P., Bergh, F., Klehmet, J., Meisel, A., Klostermann, F., Oechtering, J., Lehmann, H., Schroeter, M., Hagenacker, T., Mueller, D., Sperfeld, A., Bethke, F., Drory, I. V., Algom, A., Yarnitsky, D., Murinson, B., Di Muzio, A., Ciccocioppo, F., Sorbi, S., Mata, S., Schenone, A., Grandis, M., Lauria, G., Cazzato, D., Antonini, G., Morino, S., Cocito, D., Zibetti, M., Yokota, T., Ohkubo, T., Kanda, T., Kawai, M., Kaida, K., Onoue, H., Kuwabara, S., Mori, M., Iijima, M., Ohyama, K., Baba, M., Tomiyama, M., Nishiyama, K., Akutsu, T., Yokoyama, K., Kanai, K., van Schaik, I. N., Eftimov, F., Notermans, N. C., Visser, N., Faber, C., Hoeijmakers, J., Rejdak, K., Chyrchel-Paszkiewicz, U., Casanovas Pons, C., Antonia, M., Gamez, J., Salvado, M., Infante, C. M., Benitez, S., Lunn, M., Morrow, J., Gosal, D., Lavin, T., Melamed, I., Testori, A., Ajroud-Driss, S., Menichella, D., Simpson, E., Lai, E. C. H., Dimachkie, M., Barohn, R. J., Beydoun, S., Johl, H., Lange, D., Shtilbans, A., Muley, S., Ladha, S., Freimer, M., Kissel, J., Latov, N., Chin, R., Ubogu, E., Mumfrey, S., Rao, T., MacDonald, P., Sharma, K., Gonzalez, G., Allen, J., Walk, D., Hobson-Webb, L. & Gable, K., Sep 1 2020, In: Journal of the Peripheral Nervous System. 25, 3, p. 230-237 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Hizentra 100%
  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy 69%
  • Placebo Effect 61%
  • Polyneuropathies 58%
  • Systematic Reviews 36%
  3 Scopus citations

• Subacute sensory neuronopathy and cancer: The identification of paraneoplastic syndromes

  Kiernan, M. C. & Cornblath, D. R., Aug 1 2020, In: Journal of Neurology, Neurosurgery and Psychiatry. 91, 8, p. 793-794 2 p.

  Research output: Contribution to journal › Short survey › peer-review

  Open Access
• 2019

  Chemotherapy-induced peripheral neurotoxicity: Facts, needs and future directions

  Cavaletti, G. & Cornblath, D. R., Oct 1 2019, In: Journal of the Peripheral Nervous System. 24, S2, p. S86-S87

  Research output: Contribution to journal › Editorial › peer-review
  3 Scopus citations

• Current treatment practice of Guillain-Barré syndrome

  IGOS Consortium, Jul 2 2019, In: Neurology. 93, 1, p. E59-E76

  Research output: Contribution to journal › Article › peer-review

  • Miller Fisher Syndrome 100%
  • Plasma Exchange 78%
  • Intravenous Immunoglobulins 72%
  • Therapeutics 53%
  • Bangladesh 38%
  22 Scopus citations

• Diagnosis and management of Guillain–Barré syndrome in ten steps

  Leonhard, S. E., Mandarakas, M. R., Gondim, F. A. A., Bateman, K., Ferreira, M. L. B., Cornblath, D. R., van Doorn, P. A., Dourado, M. E., Hughes, R. A. C., Islam, B., Kusunoki, S., Pardo, C. A., Reisin, R., Sejvar, J. J., Shahrizaila, N., Soares, C., Umapathi, T., Wang, Y., Yiu, E. M., Willison, H. J., & 1 othersJacobs, B. C., Nov 1 2019, In: Nature Reviews Neurology. 15, 11, p. 671-683 13 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Guidelines 100%
  • Disease Outbreaks 91%
  • Polynesia 81%
  • Zika Virus 68%
  • Latin America 61%
  73 Scopus citations

• Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies

  on Behalf of the PRIMA Trial Investigators and the PATH Study Group, Mar 2019, In: Journal of the Peripheral Nervous System. 24, 1, p. 48-55 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Hizentra 100%
  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy 69%
  • Polyneuropathies 58%
  • Intravenous Immunoglobulins 55%
  • Safety 28%
  7 Scopus citations

• Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study

  Van Schaik, I. N., Mielke, O., Bril, V., Van Geloven, N., Hartung, H. P., Lewis, R. A., Sobue, G., Lawo, J. P., Praus, M., Durn, B. L., Cornblath, D. R. & Merkies, I. S. J., Sep 1 2019, In: Neurology: Neuroimmunology and NeuroInflammation. 6, 5

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Hizentra 100%
  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy 69%
  • Immunoglobulins 43%
  • Safety 28%
  • Recurrence 14%
  11 Scopus citations

• Neurophysiological, nerve imaging and other techniques to assess chemotherapy-induced peripheral neurotoxicity in the clinical and research settings

  on behalf of the Toxic Neuropathy Consortium (TNC), Dec 1 2019, In: Journal of Neurology, Neurosurgery and Psychiatry. 90, 12, p. 1361-1369 9 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Neural Conduction 100%
  • Drug Therapy 65%
  • Spinal Ganglia 48%
  • Nerve Fibers 43%
  • Laser-Evoked Potentials 37%
  19 Scopus citations

• Patient-reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study

  the PATH study group, 2019, (Accepted/In press) In: European Journal of Neurology.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Hizentra 100%
  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy 69%
  • Polyneuropathies 58%
  • Patient Reported Outcome Measures 54%
  • Immunoglobulins 43%
  1 Scopus citations

• Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity

  the CI-PeriNomS Group, Mar 1 2019, In: Journal of the Peripheral Nervous System. 24, 1, p. 111-119 9 p.

  Research output: Contribution to journal › Article › peer-review

  • Oncologists 100%
  • Physicians 68%
  • Drug Therapy 64%
  • Vibration 19%
  • Neurologic Examination 19%
  8 Scopus citations

• Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy

  Bunschoten, C., Jacobs, B. C., Van den Bergh, P. Y. K., Cornblath, D. R. & van Doorn, P. A., Aug 2019, In: The Lancet Neurology. 18, 8, p. 784-794 11 p.

  Research output: Contribution to journal › Review article › peer-review

  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy 100%
  • Nodal Protein 21%
  • Immunoglobulins 20%
  • Medical Overuse 14%
  • Plasma Exchange 14%
  44 Scopus citations

• Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study

  on behalf of the PATH study group, Mar 2019, In: Journal of the Peripheral Nervous System. 24, 1, p. 72-79 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Hizentra 100%
  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy 69%
  • Polyneuropathies 58%
  • Intravenous Immunoglobulins 55%
  • Random Allocation 48%
  5 Scopus citations

• Toxic neuropathies: Chemotherapy induced peripheral neurotoxicity

  Alberti, P., Cavaletti, G. & Cornblath, D. R., Oct 1 2019, In: Current opinion in neurology. 32, 5, p. 676-683 8 p.

  Research output: Contribution to journal › Review article › peer-review

  • Poisons 100%
  • Drug Therapy 79%
  • Peripheral Nerves 43%
  • Clinical Trials 29%
  • Therapeutics 22%
  3 Scopus citations

• Yield of next-generation neuropathy gene panels in axonal neuropathies

  Lee, D. C., Dankwa, L., Edmundson, C., Cornblath, D. R. & Scherer, S. S., Dec 1 2019, In: Journal of the Peripheral Nervous System. 24, 4, p. 324-329 6 p.

  Research output: Contribution to journal › Article › peer-review

  • Genes 100%
  • Polyneuropathies 48%
  • Axons 36%
  • Referral and Consultation 30%
  • Tooth 29%
  2 Scopus citations
• 2018

  231st ENMC International Workshop:: International Standard for CIDP Registry and Biobank, Naarden, The Netherlands, 12–14 May 2017

  participants of the 231st ENMC workshop, Feb 2018, In: Neuromuscular Disorders. 28, 2, p. 178-184 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  5 Scopus citations

• A randomised, multi-centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol

  Cornblath, D. R., Hartung, H. P., Katzberg, H. D., Merkies, I. S. J. & van Doorn, P. A., Jun 2018, In: Journal of the Peripheral Nervous System. 23, 2, p. 108-114 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy 100%
  • Intravenous Immunoglobulins 79%
  • Panzyga 16%
  • Adrenal Cortex Hormones 11%
  • Passive Immunization 8%
  5 Scopus citations

• IgPro20, the Polyneuropathy and Treatment with Hizentra^® study (PATH), and the treatment of chronic inflammatory demyelinating polyradiculoneuropathy with subcutaneous IgG

  Berger, M., Harbo, T., Cornblath, D. R. & Mielke, O., Aug 2018, In: Immunotherapy. 10, 11, p. 919-933 15 p.

  Research output: Contribution to journal › Article › peer-review

  • Hizentra 100%
  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy 69%
  • Polyneuropathies 58%
  • Immunoglobulin G 37%
  • Intravenous Immunoglobulins 22%
  6 Scopus citations

• Intravenous versus subcutaneous immunoglobulin – Authors' reply

  PATH study group, May 2018, In: The Lancet Neurology. 17, 5, p. 393-394 2 p.

  Research output: Contribution to journal › Letter › peer-review

• Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial

  FORCIDP Trial Investigators, Aug 2018, In: The Lancet Neurology. 17, 8, p. 689-698 10 p.

  Research output: Contribution to journal › Article › peer-review

  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy 100%
  • Fingolimod Hydrochloride 98%
  • Randomized Controlled Trials 47%
  • Intravenous Immunoglobulins 47%
  • Placebos 39%
  14 Scopus citations

• Regional variation of Guillain-Barré syndrome

  the IGOS Consortium, Oct 1 2018, In: Brain. 141, 10, p. 2866-2877 12 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Bangladesh 100%
  • Geography 26%
  • Miller Fisher Syndrome 16%
  • Health Care Outcome Assessment 13%
  • Disease Susceptibility 11%
  50 Scopus citations